Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study

Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study

BackgroundNon-small cell lung cancer (NSCLC) patients with HER2 mutations and amplification may benefit from HER2-targeted therapy, including afatinib. However, the data regarding the clinical activity of afatinib in Chinese patients with NSCLC harboring HER2 alterations are limited.Patients and met...

Full description

Bibliographic Details
Main Authors: Zhengbo Song, Dongqing Lv, Shiqing Chen, Jianhui Huang, Liping Wang, Shuguang Xu, Huafei Chen, Guoqiang Wang, Quan Lin
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer (NSCLC)
HER2
afatinib
efficacy
resistance
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.657283/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.657283/full

Similar Items